Titanovo Logo
Back to Cell Types

UM-UC-9Homo sapiens (Human)Cancer cell line

Also known as: University of Michigan-Urothelial Carcinoma-9, UC-9, UMUC9

🤖 AI SummaryBased on 6 publications

Quick Overview

Human bladder cancer cell line with known genetic mutations and drug response profiles.

Detailed Summary

UM-UC-9 is a human bladder cancer cell line derived from transitional cell carcinoma. It is characterized by specific genetic mutations, including alterations in the TERT promoter and other key cancer-related genes. This cell line has been used in studies to investigate tumor biology, drug response, and the development of therapeutic strategies. Research has shown that UM-UC-9 exhibits mutations associated with the PI3K/mTOR pathway and other critical signaling pathways, making it a valuable model for studying bladder cancer progression and treatment responses. Additionally, UM-UC-9 has been utilized in studies examining the role of telomerase activity and its implications in cancer development and therapy.

Research Applications

Tumor biology studiesDrug response profilingGenetic mutation analysisTherapeutic strategy development

Key Characteristics

TERT promoter mutationsPI3K/mTOR pathway alterationsTelomerase activity analysis
Generated on 6/19/2025

Basic Information

Database IDCVCL_2753
SpeciesHomo sapiens (Human)
Tissue SourceUrinary bladder[UBERON:UBERON_0001255]

Donor Information

Age CategoryUnknown
SexMale

Disease Information

DiseaseBladder carcinoma
LineageBladder/Urinary Tract
SubtypeBladder Urothelial Carcinoma
OncoTree CodeBLCA

DepMap Information

Source TypeSigma-Aldrich
Source IDACH-001416_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Leu348fs (c.1044delG)Unspecified-PubMed=27270441
MutationSimpleATMp.Ile2888Thr (c.8663T>C)Heterozygous-PubMed=27270441

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
12,13
D13S317
11,13
D16S539
11,13
D18S51
16,17
D21S11
29
D3S1358
14,17
D5S818
12
D7S820
9,11
D8S1179
12,14
FGA
22,25,26
Penta D
10
Penta E
7,12
TH01
9
TPOX
11
vWA
16,17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Systematic review: characteristics and preclinical uses of bladder cancer cell lines.

Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.

Bladder Cancer 4:169-183(2018).

DOIPubMedPMC

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

DOIPubMedPMC

Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response.

Tsang S.X., Cai Z.-M., Wu S., Dean M., Costello J.C., Theodorescu D.

Oncogene 36:35-46(2017).

DOIPubMedPMC

The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.

Chanock S.J., Valencia A., Real F.X.

BMC Genomics 16:403.1-403.16(2015).

DOIPubMedPMC

Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.

Orntoft T.F., Zuiverloon T.C.M., Malats N., Zwarthoff E.C., Real F.X.

Eur. Urol. 65:360-366(2014).

DOIPubMed

The use of short tandem repeat profiling to characterize human bladder cancer cell lines.

Chiong E., Dadbin A., Harris L.D., Sabichi A.L., Grossman H.B.

J. Urol. 181:2737-2748(2009).

DOIPubMedPMC

Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection.

Czerniak B.

J. Natl. Cancer Inst. 100:1401-1411(2008).

DOIPubMedPMC

Characterization of a panel of cell lines derived from urothelial neoplasms: genetic alterations, growth in vivo and the relationship of adenoviral mediated gene transfer to coxsackie adenovirus receptor expression.

Zhou J.-H., Benedict W.F., Grossman H.B.

J. Urol. 175:1133-1137(2006).

DOIPubMed

Web Resources

tcpaportal.orgsynapse.org